By using chemical methods to optimize the skin delivery of peptides, one strategy is to alter the structure of the peptide by chemical modification or complexation and creation of new compounds, and a...
Our company has received the Notice of Approval for Clinical Trials of Insulin Degludec Injection issued by the State Drug Administration*Acceptance number: [CXSL2101500]Gene-Biocon has re...
Gene-Biocon will attend the exhibition of CPHI in shanghai, Booth no. Hall3, E3E82.During the exhibition, our focus remained on expanding our Enzyme raw products with no animal origin, no miscellaneou...
Gene-Biocon had participated in CPHI, from 16 to 18 Dec 2021. Booth no. Hall3, E3E82.Our focus remained on expanding our Pharmaceutical raw products portfolio. Apart from a wide range of new Recombina...
Recently, Zhuhai Gene-Biocon have passed the review and obtained the patent authorization certificate of patent No. ZL 201811585091.4 in accordance with the Patent Law of the People...
On the meeting, the headquarter of Gene-Biocon has summarized of the work in the first half of the year. He said that: "With the cooperation of all staff of our company, Gene-Biocon has not only ...
Recently, Gene-Bicon has received the Certificate of Quality Management System Certification of ISO9001, which covering the R&D and production raw materials for protein products and peptide produc...
On 21 Aug 2020, The 9th China Innovation and Entrepreneurship Competition (Guangdong·Zhuhai Division) and the 2020 Zhuhai Science and Technology Cup Innovation and Entrepreneurship Compet...
All products from the site for Research Use Only. Not for use in diagnostic procedures.
Reproduction of any materials is strictly forbidden without permission.
We use cookies on this site, including third party cookies, to deliver experience for you.
All products from the site for Research Use Only. Not for use in diagnostic procedures.
Reproduction of any materials is strictly forbidden without permission.
